Cargando…
Synthetic Lethality in Ovarian Cancer
Ovarian cancers include several distinct malignancies which differ with respect to clinicopathologic features and prognosis. High-grade serous cancer is the most common histologic subtype and accounts for most ovarian cancer–related deaths. High-grade serous ovarian cancer (HGSOC) is treated with su...
Autores principales: | Chandrasekaran, Akshaya, Elias, Kevin M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571039/ https://www.ncbi.nlm.nih.gov/pubmed/34518297 http://dx.doi.org/10.1158/1535-7163.MCT-21-0500 |
Ejemplares similares
-
Synthetic lethality guiding selection of drug combinations in ovarian cancer
por: Heinzel, Andreas, et al.
Publicado: (2019) -
Approaches to Identifying Synthetic Lethal Interactions in Cancer
por: Thompson, Jordan M., et al.
Publicado: (2015) -
Breast Cancer Predisposition Genes and Synthetic Lethality
por: Neiger, Hannah E., et al.
Publicado: (2021) -
Epigenetic synthetic lethality approaches in cancer therapy
por: Yang, Haoshen, et al.
Publicado: (2019) -
Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
por: Liu, Marisa C, et al.
Publicado: (2018)